Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

The FIP1L1-PDGFRA oncogene is a common cause of chronic eosinophilic leukemia (CEL), and encodes an activated tyrosine kinase that is inhibited by imatinib. FIP1L1-PDGFRA–positive patients with CEL respond to low-dose imatinib therapy, but resistance due to acquired T674I mutation has been observed....

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lierman, Els, Folens, Cedric, Stover, Elizabeth H., Mentens, Nicole, Van Miegroet, Helen, Scheers, Werner, Boogaerts, Marc, Vandenberghe, Peter, Marynen, Peter, Cools, Jan
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society of Hematology 2006
Témata:
Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895882/
https://ncbi.nlm.nih.gov/pubmed/16645167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-02-004457
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky